New phase 2 trial findings published in The Lancet Diabetes & Endocrinology suggest burosumab treatment for X-linked hypophosphataemia (XLH) may begin in the first year of life. Unpick the findings in our latest article.

BREAKING NEWS: President Joe Biden just endorsed Keisha Lance Bottoms for governor! From her time as mayor to serving in the Biden Administration, Keisha has a record of delivering for Georgians. #gapol#

From the America Innovates stage, Lance Hastings, President & CEO of the California Manufacturers & Technology Association, spoke about how American can maintain its leadership in innovation. 📸: Kathleen Sheffer for Forbes ⠀ #Forbes250# #A250#

Over the course of last night, the Russian army continued to strike Ukrainian positions. As of 7 a.m., more than 140 strikes on frontline positions had been recorded. During the night, the Russians carried out 10 assaults, the largest number of them in the Slovyansk sector. They also launched more than 850 strikes with drones of various types – FPVs, “Lancets,” and others. There were attack drones as well. The use of reconnaissance drones in the skies over frontline communities also did not stop. All of this clearly shows that, on the Russian side, there was not even a token attempt to cease fire on the front. As we did over the past 24 hours, Ukraine will respond in kind today as well. We will defend our positions and people’s lives. Russia must end its war, and everyone will truly see it when movement toward peace begins. Glory to Ukraine!

Lantern Pharma $LTRN: 47% R&D Cost Reduction and FDA Regulatory Progress Signal Capital-Efficient Execution in Q1 2026 @LanternPharma reported Q1 2026 results defined by measurable operating discipline — R&D spend down 47% year-over-year — while simultaneously advancing multiple clinical and technological programs through substantive milestones. Q1 Takeaways Include: • HARMONIC™ protocol now FDA-aligned: Protocol amendments targeting the L858R mutation subgroup are designed to sharpen enrollment efficiency and strength • Starlight IND cleared: Pediatric CNS cancer program advances with potential PRV eligibility intact — a voucher that has traded at $100M+ in prior transactions • Balance sheet reinforced: Up to $9.25M in new financing extends runway and supports both clinical and AI commercialization strategies • commercially live: Multi-agentic AI co-scientist platform now available via subscription, adding a potential revenue layer to complement the clinical pipeline For investors tracking clinical-stage oncology names with AI infrastructure upside, the Q1 execution print gives $LTRN a stronger story heading into the second half of 2026. Read the full Q1 2026 results: $LTRN $SXTP $INAB $DMAC $BIVI $BFRG $NSRX $CLDI $NXL $GTBP $KYNB $ANIX